Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - rivastigmine hydrogen tartrate - capsule,hard - 6mg - rivastigmine hydrogen tartrate (8000003317) 9.6mg - rivastigmine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

n.v. organon (0000007178) kloosterstraat 6, oss, 5349 ab - mirtazapine - film coated tablets - 30mg - mirtazapine (8000001530) 30mg - mirtazapine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

n.v. organon (0000007178) kloosterstraat 6, oss, 5349 ab - montelukast sodium - tablet,chewable - 5mg - montelukast sodium (8000001574) 5,2mg - montelukast

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

n.v. organon (0000007178) kloosterstraat 6, oss, 5349 ab - montelukast sodium - film coated tablets - 10mg - montelukast sodium (8000001574) 10,4mg - montelukast

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

multi-pharm co ltd - ΚΩΔΕΐΝΗ ΦΩΣΦΟΡΙΚΌ ΆΛΑΣ, ΠΑΡΑΚΕΤΑΜΌΛΗ - tablets - 0000052288 - codeine phosphate - 20 mg; 0000103902 - paracetamol - 500 mg - paracetamol, combinations with psycholeptics

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

multi-pharm co ltd - ΠΑΡΑΚΕΤΑΜΌΛΗ, ΚΩΔΕΐΝΗ ΦΩΣΦΟΡΙΚΌ ΆΛΑΣ - capsule,hard - 0000103902 - paracetamol - 500 mg; 0000052288 - codeine phosphate - 30 mg - paracetamol, combinations with psycholeptics

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - galantamine hydrobromide - film coated tablets - 8mg - galantamine hydrobromide (0001953044) 10.253mg - galantamine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - galantamine hydrobromide - film coated tablets - 12mg - galantamine hydrobromide (0001953044) 15.379mg - galantamine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - galantamine hydrobromide - film coated tablets - 4mg - galantamine hydrobromide (0001953044) 5.126mg - galantamine

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Αντιθρομβωτικοί παράγοντες - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.